James Love's blog

Harvey Bale, former Director General of IFPMA, says Fast Track "favors the powerful over the weak"

Following the Friday vote in the House of Representatives which effectively blocked movement (for now) on the Trade Promotion Authority, and more generally, slowed down the TransPacific Partnership (TPP) negotiations, I was contacted by Dr. Harvey Bale, the well known former Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). In an exchange on Facebook, Dr. Bale took favorable note of the outcome on fast track, and described the vote against fast track as "A very good day, Indeed." I asked Dr.

Article in Medium, on the TPP

I have written an article for Medium, titled: TPP, designed to make medicine more expensive, reforms more difficult. (Link here)

2014 Oct 10: ASEAN proposals for RECP IP CHapter, also India

(More KEI RCEP leaks here: http://keionline.org/rcep)

Last week, KEI published the October 3, 2014 Korea proposals for the RCEP IP Chapter (http://www.keionline.org/node/2239), and earlier we published a Japan proposal for the RCEP IP Chapter (http://keionline.org/node/2173)

Today we are publishing two new proposals for the RCEP IP Chapter, the proposals by

US Copyright office proposes limits on damages, injunctions, for Orphan Works, contradicting TPP language

The US Copyright Office has proposed limitations on damages and injunctions, when "orphan" copyrighted works are infringed.

2014 Oct 3 version: Korea proposal for RECP IP Chapter (Regional Comprehensive Economic Partnership)

(More KEI RCEP leaks here: http://keionline.org/rcep)

Attached (here) is the October 3, 2014 version of the Draft Text, of the Intellectual Property Chapter, for the Regional Comprehensive Economic Partnership (RCEP), Free Trade Agreement, tabled by South Korea in the negotiations. (More about the RCEP here)

Put the patents at risk, not the patients

The TPP, following a plethora of other trade agreements involving the United States, the European Union and Japan as trading partners, seeks to expand and extend drug monopolies, by requiring lower standards for the grant of patents, extensions of patent terms, exclusive rights in test data, among other measures. These proposals and polices are designed to have the predictable effect of making drug prices higher.

KEI comments to DHHS on WHA agenda 17.4, the Consultative Expert Working Group on Research and Development

Re: 17.4 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Document A68/34

My name is James Love, from Knowledge Ecology International. I wanted to discuss the negotiations on new approaches to funding medical R&D.

I will begin with the much delayed discussions about a WHO R&D treaty, which are supposed to resume in 2016.

We have suggestions for some changes in the discussion, to move things forward.

USTR's 2015 Special 301 List

Every year USTR issues a list of countries targeted to be subjected to trade pressures over their policies on intellectual property rights. This year's list was published on April 30, 2015. KEI has a copy of every version of the Special 301 list here: http://www.keionline.org/ustr/special301

USTR describes the list as follows:

The Special 301 Process

OCR version of leaked EU document on : "A digital single market strategy for Europe"

Yesterday, Politico published this story:

Leaked digital single market’s ‘evidence file’ reveals Commission’s ambitions. Documents show policy came before evidence for cybersecurity measures.
By ZOYA SHEFTALOVICH 20/4/15, 1:29 PM CET Updated 21/4/15, 11:33 AM CET

The CA State Assembly Health Committee staff analysis of AB463; includes who supports and opposes

The California Assembly Health Committee has published an analysis of AB463, the Pharmaceutical Cost Transparency Act of 2015. The bill will be marked up by the committee on Tuesday (April 21). The analysis was written by Dharia McGrew. It recommends three amendments to the bill, and provides a discussion of the benefits of the required disclosures, with context, and describes the support and opposition. The staff report is attached, and below is a list of 33 groups supporting and 22 opposing the bill.

State of California considers AB463, a bill to require disclosure of drug development costs, and more economic data

This is a bill that will see legislative action next week in California, and the bill has some momentum. This is the first time I have seen any government make an effort to have useful data on the economics drug drug development and pricing, and it provides a model that other governments may want to built upon.

A mark-up on the bill has been scheduled for Tuesday, April 21, 2015, in the Assembly Health Committee.


INTRODUCED BY Assembly Member Chiu

FEBRUARY 23, 2015

Sony complains fundraiser: "smells a little bit like a Disney play regarding corp. tax reform"

This from the Wikileaks Sony Archive:

An email from Keith Weaver, the "Executive Vice President, Worldwide Government Affairs at Sony Pictures Entertainment, provide an illustration the practical art of doing "Government Affairs," meeting "goals" for fundraisers, trying to avoid making "personal" contributions, and wondering if the donations were to much focused on another company's purchase of policy" "smells a little bit like a Disney play regarding corp. tax reform".


From: Weaver, Keith
Sent: Tuesday, August 26, 2014 5:23 PM
To: Weil, Leah

2015: KEI and Public Citizen ask the NIH for safeguards in patent license for HCV drug

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses

Twenty groups write Congress, no fast track without public access to trade agreement negotiating texts

Twenty groups, including KEI, have written Congress, asking the Congress to provide public access to draft trade agreement texts and U.S. proposals throughout negotiations, and to specific that only agreements developed through such processes should obtain any expedited congressional consideration.

Among other things, the groups said:

St Jude's influenza patents, with US government rights

St Jude holds 24 patents with influenza in the specification, that also disclose US government rights. Some of these were discussed here: http://keionline.org/node/2188

PAT. NO. Title
1 8,574,592 Modified influenza virus for monitoring and improving vaccine efficiency
2 8,551,481 Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody
3 8,309,099 DNA transfection system for the generation of negative strand RNA virus

Syndicate content